Bruker Co. (NASDAQ:BRKR) Shares Acquired by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC increased its stake in Bruker Co. (NASDAQ:BRKR) by 15.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 40,522 shares of the medical research company’s stock after buying an additional 5,523 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Bruker were worth $2,798,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Covestor Ltd grew its stake in Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 210 shares in the last quarter. First Horizon Advisors Inc. grew its stake in Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 218 shares in the last quarter. UMB Bank n.a. grew its stake in Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd acquired a new stake in Bruker during the 2nd quarter valued at approximately $52,000. Finally, EverSource Wealth Advisors LLC grew its stake in Bruker by 40.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company’s stock valued at $81,000 after purchasing an additional 248 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Down 0.2 %

Shares of Bruker stock opened at $55.92 on Thursday. The business’s fifty day moving average price is $63.07 and its two-hundred day moving average price is $65.69. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The company has a market capitalization of $8.48 billion, a P/E ratio of 26.88, a PEG ratio of 2.68 and a beta of 1.20. Bruker Co. has a 1-year low of $54.55 and a 1-year high of $94.86.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). The business had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The firm’s revenue was up 16.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.74 EPS. As a group, research analysts forecast that Bruker Co. will post 2.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BRKR. Barclays lowered their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. Wells Fargo & Company reduced their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Citigroup reduced their target price on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Finally, TD Cowen reduced their target price on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Bruker presently has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.